S L KoletarSummaryAffiliation: The Ohio State University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patientsS L Koletar
The Ohio State University Medical Center, Columbus, Ohio 43210, USA
Antimicrob Agents Chemother 43:2869-72. 1999..Azithromycin is a useful alternative treatment for disseminated MAC infection in AIDS patients. Symptomatic improvement correlates with measurable decreases in mycobacterial load...- Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapySusan L Koletar
Division of Infectious Diseases, Ohio State University, Columbus, OH 43210, USA
Clin Infect Dis 39:1500-6. 2004..Descriptions of the durability and consequences of immune reconstitution in patients who start highly active antiretroviral therapy (HAART) while severely immunosuppressed are limited... - A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /lS L Koletar
The Ohio State University Hospitals, Columbus, Ohio, USA
AIDS 15:1509-15. 2001..Neither lifelong primary nor secondary PCP prophylaxis is necessary... - Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapyMitchell Goldman
Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis, Indiana 46202, USA
Clin Infect Dis 38:1485-9. 2004.... - Third-trimester maternal toxicity with nevirapine use in pregnancySaju Joy
Department of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus, OH 43210, USA
Obstet Gynecol 106:1032-8. 2005..Further study of nevirapine in larger cohorts of HIV-infected pregnant women is warranted to determine the relationship between nevirapine hepatotoxicity and trimester use. LEVEL OF EVIDENCE: II-3... - Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionRoy M Gulick
Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
AIDS 21:813-23. 2007..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection... - Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick
Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
JAMA 296:769-81. 2006..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen... - AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristicsMarlene Smurzynski
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
HIV Clin Trials 9:269-82. 2008..We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy... - Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletionHoward M Lederman
Eudowood Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Infect Dis 188:1794-803. 2003..009) and mumps skin test antigen (29% vs. 17%; P=.001). Although the subjects had only partial responses to immune function testing, the rate of opportunistic infections was very low, and none of the tests was predictive of risk... - Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicityDavid A Wohl
Department of Medicine, University of North Carolina, Chapel Hill, USA
J Acquir Immune Defic Syndr 35:274-8. 2004..This variability may reflect differences in the definition of and risk factors for hyperlactatemia and/or techniques for venous lactate collection... - A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 Alberdina W de Boer
Chiron Corporation, Emeryville, CA 94608 2916, USA
Clin Immunol 106:188-96. 2003..IL-2 therapy in cycles of 5 days resulted in an optimal increase in CD4(+) T-cell counts and is the preferred cycle length for IL-2 therapy geared toward increasing CD4(+) T-cell numbers... - Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratioKathleen Mulligan
University of California at San Francisco, San Francisco General Hospital, San Francisco, California, USA
AIDS 21:47-57. 2007..To evaluate the effects of metformin and rosiglitazone, alone or in combination, on fat distribution, insulin sensitivity, and lipids in HIV-infected patients with insulin resistance and changes in fat distribution... - Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166sDaniel R Kuritzkes
Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
J Infect Dis 195:1169-76. 2007..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens... - Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapyJudith A Aberg
Department of Medicine, Washington University School of Medicine, AIDS Clinical Trials Unit, St Louis, MO, 63108, USA
Clin Infect Dis 35:E8-E13. 2002..The low rate of these unusual MAC infections does not warrant continuation of primary or secondary prophylaxis after presumed immune reconstitution... - HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patientsJ Allen McCutchan
University of California San Diego, 150 West Washington Street, San Diego, CA 92103, USA
AIDS 21:1109-17. 2007..Epidemiological observations suggest that neuropsychological impairment might progress despite successful HAART therapy, but available prevalence estimates are based on populations that were selected for impairment... - Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta
University of Alabama at Birmingham, Birmingham, Alabama, USA
Antimicrob Agents Chemother 51:3104-10. 2007..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin... - Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG studyRob Roy MacGregor
Infectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
AIDS Res Hum Retroviruses 21:689-95. 2005..MAC-specific T cell responses apparently develop and persist during DMAC, but are dysfunctional or too infrequent to prevent persistence...
Research Grants
- The Ohio State University AIDS Clinical Trials UnitSusan Koletar; Fiscal Year: 2007..Well-designed clinical trials to test vaccines and other preventive strategies are essential to preventing the spread of HIV infection. ADMINISTRATIVE COMPONENT: ..